KR100865059B1 - 단순망막증 또는 전증식망막증의 예방제/치료제/진전억제제 - Google Patents

단순망막증 또는 전증식망막증의 예방제/치료제/진전억제제 Download PDF

Info

Publication number
KR100865059B1
KR100865059B1 KR1020017013765A KR20017013765A KR100865059B1 KR 100865059 B1 KR100865059 B1 KR 100865059B1 KR 1020017013765 A KR1020017013765 A KR 1020017013765A KR 20017013765 A KR20017013765 A KR 20017013765A KR 100865059 B1 KR100865059 B1 KR 100865059B1
Authority
KR
South Korea
Prior art keywords
group
compound
angiotensin
retinopathy
antagonistic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017013765A
Other languages
English (en)
Korean (ko)
Other versions
KR20020015315A (ko
Inventor
나까가와시즈에
나기사야스따까
이께다히또시
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20020015315A publication Critical patent/KR20020015315A/ko
Application granted granted Critical
Publication of KR100865059B1 publication Critical patent/KR100865059B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020017013765A 1999-04-28 2000-04-27 단순망막증 또는 전증식망막증의 예방제/치료제/진전억제제 Expired - Fee Related KR100865059B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
JPJP-P-1999-00121498 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (2)

Publication Number Publication Date
KR20020015315A KR20020015315A (ko) 2002-02-27
KR100865059B1 true KR100865059B1 (ko) 2008-10-23

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017013765A Expired - Fee Related KR100865059B1 (ko) 1999-04-28 2000-04-27 단순망막증 또는 전증식망막증의 예방제/치료제/진전억제제

Country Status (23)

Country Link
US (2) US7064141B1 (cg-RX-API-DMAC7.html)
EP (1) EP1197223B1 (cg-RX-API-DMAC7.html)
KR (1) KR100865059B1 (cg-RX-API-DMAC7.html)
CN (1) CN1172719C (cg-RX-API-DMAC7.html)
AT (1) ATE289204T1 (cg-RX-API-DMAC7.html)
AU (1) AU774799B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010084A (cg-RX-API-DMAC7.html)
CA (1) CA2371554C (cg-RX-API-DMAC7.html)
CZ (1) CZ301913B6 (cg-RX-API-DMAC7.html)
DE (1) DE60018186T2 (cg-RX-API-DMAC7.html)
DK (1) DK1197223T3 (cg-RX-API-DMAC7.html)
ES (1) ES2233362T3 (cg-RX-API-DMAC7.html)
HU (1) HU226948B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010923A (cg-RX-API-DMAC7.html)
NO (1) NO327446B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514855A (cg-RX-API-DMAC7.html)
PL (1) PL196895B1 (cg-RX-API-DMAC7.html)
PT (1) PT1197223E (cg-RX-API-DMAC7.html)
RU (1) RU2239454C2 (cg-RX-API-DMAC7.html)
SI (1) SI1197223T1 (cg-RX-API-DMAC7.html)
SK (1) SK286859B6 (cg-RX-API-DMAC7.html)
WO (1) WO2000066161A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108527B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
TWI349549B (en) * 2003-04-15 2011-10-01 Sankyo Co Medicament for treatment of intraocular angiopoietic disease
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
WO2006024092A1 (en) * 2004-08-31 2006-03-09 Newsouth Innovations Pty Limited Vegf inhibition
DK1814527T4 (da) * 2004-11-05 2020-12-07 Boehringer Ingelheim Int Dobbeltlagstablet omfattende telmisartan og amlodipin
RU2420280C2 (ru) * 2005-04-21 2011-06-10 Сантен Фармасьютикал Ко., Лтд Терапевтическое средство против кератоконъюнктивального расстройства
KR20080074128A (ko) * 2005-12-06 2008-08-12 산텐 세이야꾸 가부시키가이샤 각결막 장애 치료제
PT2124903T (pt) * 2007-03-28 2019-09-26 Takeda Pharmaceuticals Co Composição farmacêutica sólida compreendendo um derivado de benzimidazole-7-carboxilato e um agente de controlo de ph

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010183A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
WO1999001459A1 (en) * 1997-06-30 1999-01-14 Zambon Group S.P.A. Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
MX9603259A (es) * 1994-02-08 1997-03-29 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
NZ332008A (en) * 1996-03-29 1999-05-28 Smithkline Beecham Corp Eprosartan dihydrate and a process for its production and formulation
PL193365B1 (pl) * 1996-04-05 2007-02-28 Takeda Pharmaceutical Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz zastosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2294515C (en) * 1997-06-27 2007-08-28 Smithkline Beecham Corporation Eprosartan monohydrate
CA2299470C (en) * 1997-08-06 2010-01-26 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
EP1058541B1 (en) 1998-03-04 2004-01-28 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
EP1096932B1 (en) 1998-07-10 2007-08-29 Novartis Pharma AG Antihypertensive combination of valsartan and calcium channel blocker
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010183A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
WO1999001459A1 (en) * 1997-06-30 1999-01-14 Zambon Group S.P.A. Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
국제공개특허 제92/10183호
국제공개특허 제99/01459호

Also Published As

Publication number Publication date
NZ514855A (en) 2004-01-30
ATE289204T1 (de) 2005-03-15
MXPA01010923A (es) 2002-06-21
EP1197223A1 (en) 2002-04-17
CA2371554A1 (en) 2000-11-09
BR0010084A (pt) 2002-01-15
CN1172719C (zh) 2004-10-27
CZ301913B6 (cs) 2010-07-28
AU774799B2 (en) 2004-07-08
EP1197223B1 (en) 2005-02-16
CA2371554C (en) 2009-06-09
KR20020015315A (ko) 2002-02-27
PL196895B1 (pl) 2008-02-29
EP1197223A4 (en) 2003-10-29
AU4143400A (en) 2000-11-17
HUP0200890A3 (en) 2002-12-28
US7064141B1 (en) 2006-06-20
DE60018186T2 (de) 2005-12-29
ZA200108527B (en) 2002-10-17
NO20015257D0 (no) 2001-10-26
HUP0200890A2 (hu) 2002-11-28
DE60018186D1 (de) 2005-03-24
HU226948B1 (en) 2010-03-29
SI1197223T1 (cg-RX-API-DMAC7.html) 2005-08-31
ES2233362T3 (es) 2005-06-16
PT1197223E (pt) 2005-04-29
DK1197223T3 (da) 2005-05-30
CZ20013804A3 (cs) 2002-04-17
US20060189669A1 (en) 2006-08-24
NO327446B1 (no) 2009-06-29
WO2000066161A1 (en) 2000-11-09
PL350554A1 (en) 2002-12-16
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
CN1348385A (zh) 2002-05-08
RU2239454C2 (ru) 2004-11-10
NO20015257L (no) 2001-10-26

Similar Documents

Publication Publication Date Title
US20100120800A1 (en) Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
CZ297941B6 (cs) Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II
KR100865059B1 (ko) 단순망막증 또는 전증식망막증의 예방제/치료제/진전억제제
US5639773A (en) Ocular hypotensive agent
JP4276768B2 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
JP2002212101A (ja) 歯肉肥厚抑制剤
JPH0867674A (ja) 眼圧降下剤
EP1579872B1 (en) Body weight gain inhibitor
JPWO2000066161A1 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
HK1083587B (en) Body weight gain inhibitor
JPWO2001005428A1 (ja) 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111018

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111018

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000